FHLC — Fidelity MSCI Health Care Index ETF
Healthcare Ranked #85 of 458 tracked ETFs · Issued by Fidelity Investments
FHLC Price Performance — Growth of $10,000
Value of a $10,000 investment in FHLC over time, compared with SPY. Both lines are rebased to $10,000 on the first shared date. Based on total returns — prices are adjusted for dividends and splits, so this assumes distributions were reinvested. Hover or tap the chart for exact values.
FHLC Drawdown
The "underwater" chart: FHLC's decline from its highest prior value at each point in time. It shows how deep past losses ran and how long the fund took to recover to break-even.
What If You'd Invested in FHLC?
See what a lump sum in FHLC would have grown to, with the option to add a regular monthly contribution on top. Figures use total returns — dividends are assumed reinvested.
Past performance doesn't predict future results. Assumes contributions on the first trading day of each month, no trading costs or taxes, and reinvested distributions. History is limited to the range published in the site's daily return data.
Overview
The Fidelity MSCI Health Care Index ETF (FHLC) is a healthcare-focused fund issued by Fidelity Investments with $3.48 billion in assets under management. It holds an overall rank of #85 out of 458 tracked ETFs and sits at #4 among its 11 category peers, earning an ETFValuer grade of B. The fund’s expense ratio of 0.084% is significantly lower than the category median of 0.36%, while its dividend yield of 1.23% exceeds the median of 0.88%. Concentration in the top ten holdings accounts for 50.6% of assets, with Eli Lilly & Co representing the largest single position at 12.1%.
Price action shows the fund trading at $83.14, which is 89.0% of its 52-week range between $64.30 and $85.46. Short-term momentum has been mixed, with a 1-day decline of 1.02% contrasting against a 1-week gain of 0.17% and a 1-month rise of 4.13%. Longer-term results are stronger, as the 3-month return of 13.62% and 6-month gain of 14.85% support a year-to-date increase of 12.28%. The 1-year return of 28.08% matches the category median exactly, while the 3-year total return stands at 38.39%. The ETFValuer grade has remained unchanged at B over the last 35 tracked days, based on 3.0 years of available price history.
With a beta of 0.58, the fund has exhibited moderate sensitivity to market movements, registering an annualized volatility of 15.48%. This lower volatility profile contributes to a Sharpe ratio of 1.49, indicating efficient risk-adjusted returns relative to the risk taken. The maximum drawdown recorded is -16.87%, reflecting the peak-to-trough decline during the observation period. Liquidity is characterized by an average daily volume of 210,560 shares and a bid-ask spread of 0.12%, suggesting adequate trading conditions.
AI-generated summary based on the data on this page.
FHLC Top Holdings
| # | Holding | % of Net Assets | Value |
|---|---|---|---|
| 1 | Eli Lilly & Co | 12.13% | $346M |
| 2 | Johnson & Johnson | 8.94% | $255M |
| 3 | AbbVie Inc | 6.03% | $172M |
| 4 | UnitedHealth Group Inc | 5.42% | $155M |
| 5 | Merck & Co Inc | 4.38% | $125M |
| 6 | Amgen Inc | 3.01% | $86M |
| 7 | Thermo Fisher Scientific Inc | 2.91% | $83M |
| 8 | Gilead Sciences Inc | 2.62% | $75M |
| 9 | Intuitive Surgical Inc | 2.62% | $75M |
| 10 | Abbott Laboratories | 2.55% | $73M |
Holdings as of 2026-04-30 per the fund's most recent SEC N-PORT-P filing. Top 10 holdings make up 50.6% of net assets — a rough gauge of concentration risk (the higher this figure, the more the fund's return depends on a handful of names). To see how FHLC's holdings overlap with other ETFs you own or are considering, check the Stock Overlap tool.
Which Funds Overlap With FHLC
Holding two funds that own the same companies adds cost and complexity without adding much diversification. These tracked ETFs share the most names with FHLC's top 10 — XLV overlaps most, holding 10 of the same companies as FHLC's top 10 (50.6% of FHLC's assets).
| ETF | Name | Shared Companies | FHLC Weight | Examples |
|---|---|---|---|---|
| XLV | State Street Health Care Select Sector SPDR ETF | 10 | 50.6% | Eli Lilly & Co, Johnson & Johnson, AbbVie Inc… |
| VHT | Vanguard Health Care Index Fund ETF Shares | 9 | 48.1% | Eli Lilly & Co, Johnson & Johnson, AbbVie Inc… |
| IYH | iShares U.S. Healthcare ETF | 9 | 38.5% | Johnson & Johnson, AbbVie Inc, UnitedHealth Group Inc… |
| PPH | VanEck Pharmaceutical ETF | 4 | 31.5% | Eli Lilly & Co, Merck & Co Inc, Johnson & Johnson… |
| VTV | Vanguard Morningstar Value ETF | 3 | 20.4% | Johnson & Johnson, AbbVie Inc, UnitedHealth Group Inc |
Compares the top 10 reported holdings of each fund, so it's a floor on true overlap — two S&P 500 trackers overlap ~100% even when only 10 names are listed. Use the Stock Overlap tool to search by individual company.
Market Backdrop
10-Year Treasury Yield: 4.77% (as of 2026-09-03) — The yield on 10-year US Treasury bonds — the standard "risk-free rate" benchmark used to contextualize this fund’s Sharpe ratio and returns.
CBOE Volatility Index (VIX): 14.32 (as of 2026-09-03) — A real-time gauge of expected S&P 500 volatility over the next 30 days — useful context for this fund’s own volatility label.
Federal Funds Rate: 3.63% (as of 2026-08-01) — The Federal Reserve’s target policy rate, which anchors short-term borrowing costs across the economy.
What FHLC's Fees Cost You
FHLC charges an expense ratio of 0.08% a year, deducted automatically from the fund's value. Small percentages compound into real money — adjust the figures below to see the impact on your own numbers.
Assumes a constant gross return and no additional contributions — a simplification, but it isolates exactly what the expense ratio costs. Try the full fee calculator to model contributions and compare any two funds.
FHLC Dividend Income Estimator
FHLC currently yields 1.23%. Enter an amount to see the income that implies, or set a monthly income target to see the investment it would take.
Based on the fund's current trailing yield, which varies with price and distributions — treat it as an estimate, not a guarantee. Yields are not adjusted for tax.
FHLC Liquidity, Domicile & Tax Treatment
Liquidity: Quoted bid/ask spread is 0.12% and average daily volume is 211K/day. Tighter spreads and higher volume mean lower round-trip trading costs; this is a live-market snapshot and can widen during volatile sessions. AUM of $3.48B provides ample scale, supporting tight spreads and issuer commitment to keep the fund open.
Domicile & tax treatment: FHLC is a US-domiciled, SEC-registered ('40 Act) exchange-traded fund. Dividends and capital gains distributions are reported to US investors on Form 1099-DIV, and the fund is not subject to the PFIC reporting or UCITS-specific rules that apply to Irish- or Luxembourg-domiciled funds. Non-US investors should note that US-domiciled ETFs are generally subject to 30% US withholding tax on dividends (unless reduced by treaty) and to US estate tax exposure on the position — Irish-domiciled UCITS ETFs tracking the same index often avoid both, which is why non-US residents frequently prefer the UCITS equivalent where one exists. This is general information, not tax advice — consult a tax professional for your situation.
FHLC Performance History
| Period | Return |
|---|---|
| 1-Day | -1.02% |
| 1-Week | +0.17% |
| 1-Month | +4.13% |
| 3-Month | +13.62% |
| 6-Month | +14.85% |
| YTD | +12.28% |
| 1-Year | +28.08% |
| 3-Year | +38.39% |
How FHLC Compares to Other Healthcare ETFs
| Rank | Grade | Ticker | Name | 1-Year | Exp. Ratio | AUM |
|---|---|---|---|---|---|---|
| #53 | B |
VHT | Vanguard Health Care Index Fund ETF Shares | +27.96% | 0.09% | $21.9B |
| #61 | B |
XBI | State Street SPDR S&P Biotech ETF | +76.06% | 0.35% | $11.4B |
| #64 | B |
XLV | State Street Health Care Select Sector SPDR ETF | +26.93% | 0.08% | $43.9B |
| #85 | B |
FHLC | Fidelity MSCI Health Care Index ETF | +28.08% | 0.084% | $3.48B |
| #94 | B |
IBB | iShares Biotechnology ETF | +51.38% | 0.44% | $10.5B |
| #136 | B |
XPH | State Street SPDR S&P Pharmaceuticals ETF | +50.98% | 0.35% | $587M |
| #167 | B |
PPH | VanEck Pharmaceutical ETF | +31.04% | 0.36% | $1.03B |
| #170 | B |
IYH | iShares U.S. Healthcare ETF | +26.50% | 0.37% | $3.86B |
| #236 | C |
ARKG | ARK Genomic Revolution ETF | +89.32% | 0.75% | $2.02B |
| #390 | C |
IHF | iShares U.S. Healthcare Providers ETF | +22.57% | 0.37% | $1.23B |
| #443 | F |
IHI | iShares U.S. Medical Devices ETF | -13.06% | 0.37% | $3.47B |